A two-part vaccine designed to defeat bovine respiratory disease, a deadly condition that costs U.S. cattle producers up to $900 million a year, has received U.S. Department of Agriculture approval. A Veterinary Biologics License was issued for Titanium 5 + PH-M, which is manufactured by Diamond Animal Health of Des Moines, Iowa, and marketed and sold by Elanco Animal Health. The new vaccine protects cattle against five viruses and two bacteria most associated with bovine respiratory disease (BRD), Elanco reported Monday. Titanium 5 + PH-M provides modified-live virus protection against bovine viral diarrhea types 1 and 2, bovine respiratory syncytial virus, infectious bovine rhinotracheitis and parainfluenza3. The vaccine also protects against Mannheimia haemolytica and Pasteurella multocida bacteria. "This means veterinarians and producers can protect cattle against the important BRD-causing viruses and bacteria with just one vaccine," said Brett Terhaar, DVM, a beef technical services veterinarian with Greenfield, Ind.-based Elanco. "Producers should partner with their veterinarians to determine the best way to incorporate this new vaccine into herd-health protocols designed to fight B RD," he added. The vaccine is comprised of a viral component, Titanium 5, and the bacteria-fighting PH-M. It is approved for use in cattle at least 60 days old and comes in 10- and 50-dose packages. Elanco called bovine respiratory disease the "the No. 1 profit-robber? for cattle producers because BRD is blamed for 75 percent of feedlot morbidity and up to 75 percent of mortality. "When cattle are exposed to respiratory viruses, their immune system can be weakened,? Dr. Terhaar said. "Once that happens, M. haemolytica and P. multocida bacteria can more easily go deep into the respiratory tract. When they reach the lungs, bacterial pathogens are a major cause of serious BRD, leading to increased illness and death."
